HomeADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
$0.056
Makalipas ang Oras ng Trabaho:(8.93%)+0.0050
$0.061
Sarado: Set 12, 7:59:36 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$0.051
Sakop ng araw
$0.050 - $0.060
Sakop ng taon
$0.040 - $1.17
Market cap
14.99M USD
Average na Volume
68.32M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 13.68M | -89.33% |
Gastos sa pagpapatakbo | 18.48M | -3.13% |
Net na kita | -30.34M | -143.64% |
Net profit margin | -221.83 | -509.13% |
Kita sa bawat share | -0.12 | -150.00% |
EBITDA | -27.78M | -138.88% |
Aktuwal na % ng binabayarang buwis | -2.06% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 26.06M | -87.87% |
Kabuuang asset | 130.63M | -59.39% |
Kabuuang sagutin | 201.59M | -10.57% |
Kabuuang equity | -70.96M | — |
Natitirang share | 265.05M | — |
Presyo para makapag-book | -0.19 | — |
Return on assets | -52.45% | — |
Return on capital | 1,376.60% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -30.34M | -143.64% |
Cash mula sa mga operasyon | -34.78M | -173.38% |
Cash mula sa pag-invest | 18.49M | 2,588.56% |
Cash mula sa financing | 1.65M | -93.25% |
Net change in cash | -15.23M | -121.40% |
Malayang cash flow | -23.84M | -135.30% |
Tungkol
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Itinatag
2008
Website
Mga Empleyado
506
